

RANDOMIZED CONTROLLED TRIAL

A Multinational Multicenter, Randomized, Double-Blinded Placebo-Controlled Trial to Evaluate the Efficacy of Cyclical Topical Wound Oxygen Therapy (TWO2) in the Treatment of Chronic Diabetic Foot Ulcers: The TWO2 Study

Robert G. Frykberg, Peter J. Franks, Michael Edmonds, Jonathan N. Brantley, Luc Teot, Thomas Wild, Matthew G. Garoufalis, Aliza M. Lee, Janette A. Thompson, Gerard Reach, Cyaandi R. Dove, Karim Lachgar, Dirk Grotemeyer, and Sophie C. Renton, on behalf of the TWO $_2$ Study Group

Study received perfect Cochrane Score for Quality of Research



PROVEN SUSTAINED HEALING






*Compared to Standard of Care (SOC) alone

RESEARCH DESIGN:

Patients with diabetes and chronic DFUs were randomized (double-blind) to either active TWO₂ therapy or sham control therapy – both in addition to optimal Standard of Care (SOC).

- The study used a group sequential design with three predetermined analyses and hard stopping rules at 73, 146 and 220 patients on completing a 12-week intention-to-treat (ITT) phase (p < 0.022 at each analysis point). All data analysis utilized an intention-to-treat (ITT) approach.
- Patients meeting eligibility criteria were enrolled into a 2-week run-in with defined optimal SOC alone.



RESULTS:

- TWO₂ was shown to be 6 times more likely to heal a DFU at 12 weeks compared to optimal SOC alone, after adjusting for ulcer severity. At 12 months, 56% of Active arm ulcers were closed compared to 27% of the Sham arm ulcers (p=0.013).
- TWO₂ demonstrated more durable healing with a 6 times lower recurrence rate compared to optimal SOC alone, with only 6.7% of Active TWO₂-treated ulcers vs. 40% of Sham TWO₂-treated ulcers recurring at 12 months.
- The wound-care-focused Quality of Life (QOL) index improved for patients whose ulcers healed with Active TWO₂ treatment in all functional domains, with the greatest improvement seen in the well-being component that improved 90-fold.
- TWO₂ therapy was shown to be safe and without complications.

PRIMARY ENDPOINT OF ULCERS 100% HEALED AT 12 WEEKS


- Active TWO₂ = 41.7% healed vs. Sham TWO₂ = 13.5% healed (Pearson Ch2 = 7.27, p = 0.007)
 - Odds ratio (OR) of 4.57 (97.8% CI 1.19, 17.57), p = 0.010
 - After adjustment for University of Texas Classification (UTC) ulcer grade, odds ratio (OR) increased to 6.00 (97.8% CI 1.44, 24.93), p = 0.004








TWO₂ ACTIVE ARM LARGER WOUND HEALING TRAJECTORIES



TWO₂ SHAM ARM LARGER WOUND HEALING TRAJECTORIES



CONCLUSION:

This sham-controlled, double-blinded RCT demonstrates that, at 12 weeks and 12 months, adjunctive cyclical pressurized TWO₂ therapy was superior in healing chronic DFUs compared with optimal SOC alone.

REFERENCE

 Frykberg R, Franks P, et al. A multinational, multicenter, randomized, double-blinded, placebo-controlled trial to evaluate the efficacy of cyclical Topical Wound Oxygen (TWO2) therapy in the treatment of chronic diabetic foot ulcers: the TWO2 study. Diabetes Care, 2020.



Visit www.AOTInc.net for more information.



